Omniose
Omniose is an innovative biotechnology company specializing in bioconjugation platforms for vaccine development. Founded in 2016, it leverages proprietary enzyme-based bioconjugation technology to create high-quality vaccines against serious bacterial pathogens, including multidrug-resistant strains. The company collaborates with major industry players like AstraZeneca and has received over $11M in SBIR/STTR grants to fuel its R&D pipeline. Omniose's mission is to develop next-generation vaccines to combat antibiotic resistance and bacterial diseases.
Industries
Nr. of Employees
small (1-50)
Products
Bioconjugate Vaccine Platform
A technology for creating vaccines by enzymatically attaching bacterial polysaccharides to carrier proteins within E. coli cells.
Vaccines against Group B Streptococcus
A vaccine developed using Omniose's platform targeting Group B Streptococcus bacteria.
Vaccines against Klebsiella pneumoniae
A vaccine targeting Klebsiella pneumoniae, developed with Omniose's bioconjugation technology.
Vaccines against Streptococcus pneumoniae
A vaccine created to target Streptococcus pneumoniae using the company's proprietary technology.
Bioconjugate Vaccine Platform
A technology for creating vaccines by enzymatically attaching bacterial polysaccharides to carrier proteins within E. coli cells.
Vaccines against Group B Streptococcus
A vaccine developed using Omniose's platform targeting Group B Streptococcus bacteria.
Vaccines against Klebsiella pneumoniae
A vaccine targeting Klebsiella pneumoniae, developed with Omniose's bioconjugation technology.
Vaccines against Streptococcus pneumoniae
A vaccine created to target Streptococcus pneumoniae using the company's proprietary technology.
News & Updates
Omniose has entered an exclusive collaboration with AstraZeneca, granting AstraZeneca rights to Omniose’s bioconjugation platform for up to three years to develop vaccines against bacterial pathogens, including multidrug-resistant bacteria.
Omniose received a significant NIH grant to support the development of vaccines targeting Group B Streptococcus, a major cause of neonatal infections.
Omniose secured a NIH grant to advance vaccine development against Klebsiella pneumoniae, a pathogen with high antimicrobial resistance.
Omniose has entered an exclusive collaboration with AstraZeneca, granting AstraZeneca rights to Omniose’s bioconjugation platform for up to three years to develop vaccines against bacterial pathogens, including multidrug-resistant bacteria.
Omniose received a significant NIH grant to support the development of vaccines targeting Group B Streptococcus, a major cause of neonatal infections.
Omniose secured a NIH grant to advance vaccine development against Klebsiella pneumoniae, a pathogen with high antimicrobial resistance.